Disease relevance of sertraline

• Sertraline and hyponatremia [1].
• Elevated serum thyrotropin in thyroxine-treated patients with hypothyroidism given sertraline [2].
• OBJECTIVE: To evaluate the safety and efficacy of sertraline treatment of MDD in patients hospitalized for acute myocardial infarction (MI) or unstable angina and free of other life-threatening medical conditions [3].
• Sertraline treatment of major depression in patients with acute MI or unstable angina [3].
• Sudden chest pain with sertraline [4].

Psychiatry related information on sertraline

• Efficacy and safety of sertraline treatment of posttraumatic stress disorder: a randomized controlled trial [5].
• Sertraline in children and adolescents with obsessive-compulsive disorder: a multicenter randomized controlled trial [6].
• Relapse of depressive symptoms after discontinuing sertraline [7].
• Sertraline in the treatment of panic disorder: a flexible-dose multicenter trial [8].
• The sertraline-treated group had greater improvements in the scores for the Cornell Scale for Depression in Dementia (P =.002) and Hamilton Depression Rating Scale (P =.01), and a statistical trend toward less decline in activities of daily living on the Psychogeriatric Depression Rating Scale-activities of daily living subscale (P =.07) [9].

High impact information on sertraline

• Sertraline and breast-feeding [10].
• Similar effectiveness of paroxetine, fluoxetine, and sertraline in primary care: a randomized trial [11].
• Exacerbations of neurally mediated syncope associated with sertraline [12].
• Sertraline and platelet counts in idiopathic thrombocytopenia purpura [13].
• Sertraline for Prevention of Depression Recurrence in Diabetes Mellitus: A Randomized, Double-blind, Placebo-Controlled Trial [14].

Chemical compound and disease context of sertraline

• We examined the efficacy and safety of the serotonin selective reuptake inhibitor sertraline hydrochloride in patients with panic disorder [8].
• The purpose of this study was to test the efficacy of early coadministration of clonazepam with sertraline in the treatment of panic disorder [15].
• SIADH associated with fluoxetine and sertraline therapy [16].
• Risk of switch in mood polarity to hypomania or mania in patients with bipolar depression during acute and continuation trials of venlafaxine, sertraline, and bupropion as adjuncts to mood stabilizers [17].
• The purpose of our study was to determine whether the serotonin reuptake inhibitor sertraline hydrochloride could prevent neurocardiogenic syncope in children and adolescents resistant to or intolerant of other therapies [18].

Biological context of sertraline

• METHOD: Patients who met symptom criteria and reported impaired functioning after three screening cycles were randomly assigned to three cycles of double-blind, placebo-controlled treatment with continuous (full-cycle dosing) or intermittent (luteal-phase dosing) sertraline [19].
• RESULTS: The safety profiles of the two treatments were similar except that nortriptyline treatment was associated with a significant increase in pulse rate, whereas sertraline was associated with a nonsignificant decrease [20].
• METHOD: The extent of maternal and infant transporter blockade was assessed by measurement of platelet levels of 5-HT in 14 breast-feeding mother-infant pairs before and after 6-16 weeks of maternal treatment with sertraline for major depression with postpartum onset [21].
• OBJECTIVE: The authors' goal was to determine whether sertraline attenuates the increased platelet activation seen among depressed patients [22].
• Prolonged bleeding time in a patient treated with sertraline [23].

Anatomical context of sertraline

• The serotonin content of the hippocampus was unaffected by paroxetine or sertraline treatment, ruling out neurotoxicity as a possible explanation for the SSRI-induced decrease in SERT binding and alteration in 5-HT clearance [24].
• This study determined the degree of transporter blockade in infants exposed to sertraline through maternal breast milk [21].
• The finding that sertraline but not bupropion slightly decreased cerebrospinal fluid hypocretin-1 indicates a serotoninergic influence on hypocretin tone [25].
• Sertraline was associated with a significantly increased relative metabolic rate in right parietal lobe and in left occipital area 19, and a decreased metabolic rate in right occipital area 18 [26].
• Other areas that differed between controls and a larger cohort of 39 depressive patients--including medial frontal lobe, cingulate gyrus, and thalamus--also showed a normalization of metabolic rate after sertraline [26].

Associations of sertraline with other chemical compounds

• CONCLUSIONS: The SRI sertraline was more effective in reducing MDD and OCD symptoms than the primarily norepinephrine reuptake inhibitor desipramine for patients with concurrent OCD and MDD [27].
• We show that some antihistaminic compounds (hydroxyzine and promethazine) and other pharmacological compounds with a related structure (including thioridazine and sertraline) kill tumor cells and significantly decrease the level of TCTP [28].
• Chronic (21 d), but not acute (1 d), administration of several different antidepressant drugs, including tranylcypromine, sertraline, desipramine, or mianserin, significantly increased BDNF mRNA and all but mianserin increased trkB mRNA in hippocampus [29].
• RESULTS: Sertraline and desmethylsertraline were present in all breast milk samples, with a gradient from "fore" milk to "hind" milk [30].
• METHODS: One hundred fifty-six men and women with MDD (age, > or = 50 years) were assigned randomly to a program of aerobic exercise, antidepressants (sertraline hydrochloride), or combined exercise and medication [31].

Gene context of sertraline

• Clinical investigations (with desipramine) confirmed in vitro findings that CYP2D6 inhibition by sertraline is only moderate [32].
• These results suggest that sertraline at the maximum recommended dosage under steady-state conditions, and demethylsertraline, the principal metabolite of sertraline, are unlikely to exert significant inhibitory effects on the CYP2C19 and CYP3A3/4 hepatic isoenzymes responsible for the metabolism of diazepam [33].
• The extent and determinants of changes in CYP2D6 and CYP1A2 activities with therapeutic doses of sertraline [34].
• All three antidepressants significantly reduced IFN gamma secretion, whereas clomipramine and sertraline significantly increased IL-10 secretion in culture supernatant [35].
• The observations reported here suggest that fluoxetine and sertraline would have little effect on CYP3A-mediated clearance of coadministered drugs [36].

Analytical, diagnostic and therapeutic context of sertraline

• CONCLUSIONS: Pharmacotherapy provides considerable relief from the symptoms of dysthymia in patients suffering from this chronic affective disorder, with both sertraline and imipramine being more effective than placebo [37].
• Episodes of MDD that began prior to ACS responded more frequently to sertraline than to placebo (63% vs 46%, respectively; odds ratio, 2.0; 95% confidence interval, 1.13-3.55) whereas depression with onset beginning after hospitalization showed a high placebo response rate (69% vs 60%, respectively) and low sertraline-placebo response ratio (1.15) [38].
• Sertraline for social phobia: a double-blind, placebo-controlled crossover study [39].
• METHOD: Adult outpatients with generalized social phobia (N=204) from 10 Canadian centers were randomly assigned to receive sertraline or placebo in a 2:1 ratio for a 20-week double-blind study following a 1-week, single-blind, placebo run-in [40].
• Platelet secretion in response to collagen was significantly reduced after treatment with sertraline [22].

References